v3.8.0.1

Stockholders’ Equity | 9 Months Ended
--- | ---
Sep. 30, 2017
Equity [Abstract] |
Stockholders’ Equity | Stockholders’ Equity Stock-Based Compensation The following table summarizes stock-based compensation in our accompanying condensed consolidated statements of operations (in thousands):
| Three Months Ended |  | Nine Months Ended
| September 30, 2017 |  | September 24, 2016 |  | September 30, 2017 |  | September 24, 2016
Cost of revenue | $ | 117 |  |  | $ | 79 |  |  | $ | 314 |  |  | $ | 233 |
Selling and marketing | 287 |  |  | 232 |  |  | 828 |  |  | 646 |
Research and development | 487 |  |  | 284 |  |  | 1,138 |  |  | 793 |
General and administrative | 2,144 |  |  | 1,156 |  |  | 4,306 |  |  | 3,093 |
Loss (income) from discontinued operations | — |  |  | — |  |  | — |  |  | 8 |
Total stock-based compensation | $ | 3,035 |  |  | $ | 1,751 |  |  | $ | 6,586 |  |  | $ | 4,773 |
Pursuant to our 2014 Incentive Award Plan (the “2014 Plan”), during the nine months ended September 30, 2017, we granted 0.5 million time-based restricted stock units (RSUs) to certain employees, advisors and directors, 0.4 million performance-based RSUs (“PSUs”) to certain members of management, and 0.2 million market-based RSUs (“MSUs”) to senior management. In the first quarter of fiscal 2017, we issued 0.4 million PSUs. The number of PSUs that become eligible to vest for each recipient will be determined in the first quarter of 2018 based upon the Company’s level of achievement of certain financial targets for fiscal 2017. To the extent any PSUs become eligible to vest, they generally will vest over a three-year period retroactive to March 2017 as continued services are performed. Management is recognizing expense using the graded-vesting method based on its estimate of the number of PSUs that will vest. If there is a change in the estimate of the number of PSUs that are probable of vesting, we will cumulatively adjust compensation expense in the period that the change in estimate is made. In the second quarter of fiscal 2017, we issued 0.2 million MSUs to senior management. The MSUs awarded will vest at any point during a five-year performance period, from 2017 through 2022, based on achievement of specified 120-day volume-weighted average closing share price targets, which is a market condition, or a change-in-control event, and if vested, will be issued in the form of common stock. The MSUs were valued at $11.18 - $12.20 per share using the Monte Carlo simulation model for the specified price targets. The stock-based compensation expense associated with the MSUs will be recognized over a weighted average derived service period of 1.14 - 1.54 years. If the market condition or the performance condition is not achieved during the five-year performance period, then the shares will be forfeited. RSUs are not included in issued and outstanding common stock until the shares are vested and released. With the exception of MSUs, the fair value of an RSU and PSU is measured based on the market price of the underlying common stock as of the date of grant, reduced by the purchase price of $0.001 per share. The weighted-average grant-date fair value per vested RSU and PSU share and the total fair value of vested shares from RSU and PSU grants was $7.59 and $3.2 million, res pectively, for the nine months ended September 30, 2017. During the nine months ended September 30, 2017, we granted 1.0 million stock options to certain employees and directors with a weighted average exercise price per share of $12.82. During the nine months ended September 24, 2016, we granted 1.4 million stock options to certain employees and directors with a weighted average exercise price per share of $6.68. The following table presents the assumptions used to estimate the fair value of options granted during the periods presented:
| Nine Months Ended
| September 30, 2017 |  | September 24, 2016
Risk-free interest rate | 1.86% - 2.18% |  | 1.19 - 1.63 %
Expected term (years) | 6.25 |  | 6.25
Volatility | 32.0% - 33.4% |  | 33.8% - 38.2%
Expected dividend yield | — |  | —
A summary of stock option, RSU, PSU, and MSU activity for the nine months ended September 30, 2017 was as follows (in thousands for shares and intrinsic value):
|  |  |  |  |  |  |  |  | Restricted Stock Units
| Shares |  | Weighted-Average Remaining Contractual Term (Years) |  | Weighted-Average Exercise Price |  | Aggregate Intrinsic Value |  | Shares |  | Weighted-Average Grant Date Fair Value
Outstanding as of December 31, 2016 | 4,312 |  |  | 6.45 |  | $ | 6.64 |  |  | $ | 13,042 |  |  | 1,780 |  |  | $ | 7.08 |
Granted(1) | 974 |  |  |  |  | $ | 12.82 |  |  |  |  | 1,085 |  |  | $ | 11.59 |
Settled (RSUs and PSUs) | — |  |  |  |  | — |  |  |  |  | (421 | ) |  | $ | 7.59 |
Exercised | (583 | ) |  |  |  | $ | 4.47 |  |  |  |  | — |  |  | — |
Canceled and forfeited | (215 | ) |  |  |  | $ | 12.72 |  |  |  |  | (541 | ) |  | $ | 7.08 |
Outstanding as of September 30, 2017 | 4,488 |  |  | 6.69 |  | $ | 7.97 |  |  | $ | 36,960 |  |  | 1,903 |  |  | $ | 9.54 |
Vested and exercisable as of September 30, 2017 | 2,769 |  |  | 5.29 |  | $ | 6.64 |  |  | $ | 26,869 |  |  | N/A |  | N/A
____________________________ (1) For RSUs, includes time-based, performance-based, and market-based restricted stock units Aggregate intrinsic value represents the difference between the closing stock price of our common stock and the exercise price of outstanding, in-the-money options. Our closing stock price as reported on the New York Stock Exchange as of September 29, 2017, the final trading day of the nine months ended September 30, 2017, was $15.89. The total intrinsic value of options exercised and RSUs and PSUs vested was approximately $10.4 million for the nine months ended September 30, 2017. The aggregate fair value of the options that vested during the nine months ended September 30, 2017 was $1.7 million. As of September 30, 2017, total unrecognized compensation cost related to non-vested stock options and RSUs was approximately $6.4 million and $14.9 million, respectively, which is expected to be recognized over a weighted-average period of 2.8 years and 2.3 years, respectively, to the extent they are probable of vesting. As of September 30, 2017, we had 2.5 million shares available for grant under the 2014 Plan. Common Stock As of September 30, 2017, we had reserved the following shares of common stock for future issuance in connection with the following (in thousands):
| September 30, 2017
Options issued and outstanding | 4,488 |
Restricted stock units issued and outstanding | 1,903 |
Common stock available for stock-based award grants under incentive award plans | 2,490 |
Common stock available for conversion of Series A Redeemable Convertible Preferred Stock | 4,724 |
Total | 13,605 |

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration